On May 6, the National Institute of Intellectual Property (INPI) issued ReST Therapeutics and its academic co-owners (University of Montpellier, INSERM, and the Ecole Pratique des Hautes Etudes) a patent on neuroprotection.
ReST Therapeutics’ project is to develop a proprietary drug candidate for the treatment of Post-Traumatic Syndrome and Alzheimer’s disease. The molecule, FENM®, initially developed as a biomarker of the brain receptor NMDA* has given very promising results in preclinical trials conducted simultaneously in France (with the University of Montpellier and the Ecole Normale Supérieure de Paris-PSL) and in the United States (with Columbia University). FENM also has protective properties against cellular and cognitive damage associated with neurodegenerative diseases such as Alzheimer’s disease, which this new patent protects.
“Obtaining this patent that we will now extend, based on the very favorable international research report we have obtained, demonstrates the strength of our innovation and supports, combined with the very good tolerance observed in the regulatory studies, our prospect of a first human administration (FIH) in 2023. It allows us to look forward with serenity to the next fundraising that we will make at this time to implement the clinical demonstration on PTSD,” said Gilles Rubinstenn, Founding President of ReST Therapeutics.
* NMDA receptors are ionotropic receptors essential to the memory and synaptic plasticity.